Targeted therapy
Topic Chair: Simon Shorvon (United Kingdom)
- Targeting genes – Renzo Guerrini (Italy)
- Targeting novel receptors – Mike Rogawski (USA)
- Targeting epileptogenesis – Asla Pitkanen (Finland)
- Targeting systems – Mark Cook (Australia)
Tauopathies and epilepsy
Topic Chair: Matthew Walker (United Kingdom)
- The physiological and pathophysiological relevance of Tau – Gabor Kovacs (Austria)
- The role of Tau in epileptogenesis – Terence O’Brien (Australia)
- The role of Tau in human epilepsy – Matthias Koepp (United Kingdom)
- The impact of seizures on Alzheimer’s – Andrew Cole (USA)
Advances in the development of diagnostic and prognostic biomarkers for childhood onset epilepsies
Topic Chair: Martha Feucht (Austria)
- Biomarkers for seizure and developmental outcomes in early onset childhood epilepsies – lessons learned from our patients – Sergiusz Jozwiak (Poland)
- Biomarkers for recognition of candidacy for epilepsy surgery – Helen Cross (United Kingdom)
- Biomarkers for seizure freedom after epilepsy surgery – Julia Jacobs (Germany)
- Prediction of seizure recurrence and long-term outcome after AED withdrawal in seizure-free patients – Kees Braun (Netherlands)
Acquired epilepsies: mechanisms, therapeutic advances and unmet needs
Topic Chair: Alla Guekht (Russia)
- Susceptibility and consequences of acquired epilepsies: does gender play a role? – Piero Perucca (Australia)
- Comorbidities and the neurobiological basis for epilepsies after brain lesions – Alla Guekht (Russia)
- Blood-brain barrier dysfunction and epileptogenesis – Alon Friedman (Israel/Canada)
- Prevention or modification of epileptogenesis after brain insults: clinical perspective – Eugen Trinka (Austria)